Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Jennison Associates LLC

Jennison Associates LLC lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 1.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 447,098 shares of the company’s stock after buying an additional 5,936 shares during the period. Jennison Associates LLC owned approximately 0.82% of Vera Therapeutics worth $19,762,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in VERA. Price T Rowe Associates Inc. MD bought a new position in shares of Vera Therapeutics in the first quarter worth $103,189,000. Vanguard Group Inc. lifted its holdings in Vera Therapeutics by 31.5% in the first quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock worth $92,653,000 after purchasing an additional 515,106 shares during the period. Samlyn Capital LLC grew its position in Vera Therapeutics by 90.8% in the 2nd quarter. Samlyn Capital LLC now owns 1,231,911 shares of the company’s stock valued at $44,571,000 after buying an additional 586,410 shares in the last quarter. First Light Asset Management LLC increased its stake in Vera Therapeutics by 130.6% during the 2nd quarter. First Light Asset Management LLC now owns 1,005,723 shares of the company’s stock valued at $36,387,000 after buying an additional 569,590 shares during the period. Finally, Logos Global Management LP boosted its holdings in shares of Vera Therapeutics by 65.2% in the second quarter. Logos Global Management LP now owns 950,000 shares of the company’s stock valued at $34,371,000 after acquiring an additional 375,000 shares in the last quarter. 99.21% of the stock is owned by institutional investors.

Analysts Set New Price Targets

VERA has been the topic of several research analyst reports. Scotiabank began coverage on Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wells Fargo & Company initiated coverage on shares of Vera Therapeutics in a research note on Thursday. They issued an “overweight” rating and a $70.00 price objective on the stock. Finally, Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Vera Therapeutics presently has an average rating of “Buy” and a consensus target price of $59.22.

Vera Therapeutics Stock Up 2.7 %

VERA stock opened at $48.31 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The firm has a market capitalization of $3.06 billion, a P/E ratio of -18.51 and a beta of 1.03. Vera Therapeutics, Inc. has a 52-week low of $12.28 and a 52-week high of $51.61. The company’s 50 day simple moving average is $43.47 and its 200-day simple moving average is $39.58.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.21). As a group, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.85 EPS for the current year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 15,000 shares of Vera Therapeutics stock in a transaction on Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the completion of the sale, the director now owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marshall Fordyce sold 23,125 shares of the company’s stock in a transaction on Wednesday, September 25th. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares in the company, valued at $14,182,110.60. This trade represents a 6.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 89,927 shares of company stock valued at $3,800,796. Company insiders own 21.70% of the company’s stock.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.